E-viri
PDF
Recenzirano
Odprti dostop
-
Wu, Yi-Long; Tsuboi, Masahiro; He, Jie; John, Thomas; Grohe, Christian; Majem, Margarita; Goldman, Jonathan W; Laktionov, Konstantin; Kim, Sang-We; Kato, Terufumi; Vu, Huu-Vinh; Lu, Shun; Lee, Kye-Young; Akewanlop, Charuwan; Yu, Chong-Jen; de Marinis, Filippo; Bonanno, Laura; Domine, Manuel; Shepherd, Frances A; Zeng, Lingmin; Hodge, Rachel; Atasoy, Ajlan; Rukazenkov, Yuri; Herbst, Roy S
The New England journal of medicine, 10/2020, Letnik: 383, Številka: 18Journal Article
The incidence of recurrence after curative resection among patients with stage IB, II, or IIIA non–small-cell lung cancer is high and is only slightly lower with adjuvant chemotherapy. A randomized trial of adjuvant osimertinib involving patients with EGFR mutation–positive NSCLC showed a substantial decrease in recurrence. Central nervous system relapses were also significantly reduced.
